-
2
-
-
77951010885
-
Aggressive lymphomas
-
Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010; 362:1417-1429.
-
(2011)
N Engl J Med
, vol.362
, pp. 1417-1429
-
-
Lenz, G.1
Staudt, L.M.2
-
3
-
-
47649096056
-
Gene expression differences between low and high stage diffuse large B cell lymphoma (DLBCL)
-
Abstract 809
-
Roberts RA, Rimsza LM, Staudt L, et al. Gene expression differences between low and high stage diffuse large B cell lymphoma (DLBCL). Blood. 2006;108:Abstract 809.
-
(2006)
Blood
, vol.108
-
-
Roberts, R.A.1
Rimsza, L.M.2
Staudt, L.3
-
4
-
-
77957200763
-
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte
-
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-2045.
-
(2011)
Blood
, vol.116
, pp. 2040-2045
-
-
Coiffier, B.1
Thieblemont, C.2
Van Den Neste, E.3
-
5
-
-
0032474694
-
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
-
Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
-
(1998)
N Engl J Med
, vol.339
, pp. 21-26
-
-
Miller, T.P.1
Dahlberg, S.2
Cassady, J.R.3
-
6
-
-
0003242248
-
CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial
-
Miller TP, LeBlanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood. 2001;98:724aY725a.
-
(2001)
Blood
, vol.98
-
-
Miller, T.P.1
Leblanc, M.2
Spier, C.3
-
7
-
-
0027444652
-
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
-
Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
-
(1993)
N Engl J Med
, vol.329
, pp. 987-994
-
-
Ma, S.1
Harrington, D.P.2
Anderson, J.R.3
-
8
-
-
77952477025
-
Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
-
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-2380.
-
(2011)
J Clin Oncol
, vol.28
, pp. 2373-2380
-
-
Ziepert, M.1
Hasenclever, D.2
Kuhnt, E.3
-
9
-
-
0036137935
-
Brief chemotherapy and involvedregion irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency
-
Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involvedregion irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20:197-204.
-
(2002)
J Clin Oncol
, vol.20
, pp. 197-204
-
-
Shenkier, T.N.1
Voss, N.2
Fairey, R.3
-
10
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
11
-
-
33745982067
-
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
-
Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3121-3127
-
-
Habermann, T.M.1
Weller, E.A.2
Morrison, V.A.3
-
12
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
-
(2006)
Lancet Oncol
, vol.7
, pp. 379-391
-
-
Pfreundschuh, M.1
Trumper, L.2
Osterborg, A.3
-
13
-
-
24644500086
-
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
-
Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23:5027-5033.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5027-5033
-
-
Sehn, L.H.1
Donaldson, J.2
Chhanabhai, M.3
-
14
-
-
33744800503
-
Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP)
-
Sehn LH, Chhanabhai M, Fitzgerald C, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP). Blood. 2005;106:147a.
-
(2005)
Blood
, vol.106
-
-
Sehn, L.H.1
Chhanabhai, M.2
Fitzgerald, C.3
-
15
-
-
44249092120
-
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
-
Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258-2263.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2258-2263
-
-
Persky, D.O.1
Unger, J.M.2
Spier, C.M.3
-
16
-
-
0019840126
-
Survival of patients with localized diffuse histiocytic lymphoma
-
Sweet DL, Kinzie J, Gaeke ME, et al. Survival of patients with localized diffuse histiocytic lymphoma. Blood. 1981;58:1218-1223.
-
(1981)
Blood
, vol.58
, pp. 1218-1223
-
-
Sweet, D.L.1
Kinzie, J.2
Gaeke, M.E.3
-
17
-
-
0021955804
-
Long-termsurvival of patients with localized diffuse histiocytic lymphoma
-
Vokes EE, Ultmann JE, GolombHM, et al. Long-termsurvival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol. 1985; 3:1309-1317.
-
(1985)
J Clin Oncol
, vol.3
, pp. 1309-1317
-
-
Vokes, E.E.1
Ultmann, J.E.2
Golomb, H.M.3
-
18
-
-
0023261426
-
Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma
-
Connors JM, Klimo P, Fairey RN, et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med. 1987;107:25-30.
-
(1987)
Ann Intern Med
, vol.107
, pp. 25-30
-
-
Connors, J.M.1
Klimo, P.2
Fairey, R.N.3
-
19
-
-
0020619345
-
A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas
-
Nissen NI, Ersboll J, Hansen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer. 1983;52:1-7.
-
(1983)
Cancer
, vol.52
, pp. 1-7
-
-
Nissen, N.I.1
Ersboll, J.2
Hansen, H.S.3
-
20
-
-
20144369743
-
ACVBP versusCHOP plus radiotherapy for localized aggressive lymphoma
-
Reyes F, Lepage E,GanemG, et al. ACVBP versusCHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197-1205.
-
(2005)
N Engl J Med
, vol.352
, pp. 1197-1205
-
-
Reyes, F.1
Lepage, E.2
Ganem, G.3
-
21
-
-
4143102674
-
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484
-
Horning SJ,Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032-3038.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3032-3038
-
-
Horning, S.J.1
Weller, E.2
Kim, K.3
-
22
-
-
33947543250
-
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte
-
Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:787-792.
-
(2007)
J Clin Oncol
, vol.25
, pp. 787-792
-
-
Bonnet, C.1
Fillet, G.2
Mounier, N.3
-
23
-
-
0033566341
-
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
-
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433.
-
(1999)
Blood
, vol.94
, pp. 429-433
-
-
Jerusalem, G.1
Beguin, Y.2
Fassotte, M.F.3
-
24
-
-
77957940539
-
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
-
Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28:4170-4176.
-
(2011)
J Clin Oncol
, vol.28
, pp. 4170-4176
-
-
Phan, J.1
Mazloom, A.2
Medeiros, L.J.3
-
25
-
-
80053384016
-
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-1022.
-
(2011)
Lancet Oncol
, vol.12
, pp. 1013-1022
-
-
Pfreundschuh, M.1
Kuhnt, E.2
Trumper, L.3
-
26
-
-
69549152853
-
Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313)
-
abstract 3598
-
Miller TP, Unger JM, Spier C, et al. Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313). Blood. 2008;112:abstract 3598.
-
(2008)
Blood
, vol.112
-
-
Miller, T.P.1
Unger, J.M.2
Spier, C.3
-
27
-
-
80053555137
-
New strategies in diffuse large B-cell lymphoma: Translating findings from gene expression analyses into clinical practice
-
Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res. 2011;17:6112-6117.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6112-6117
-
-
Friedberg, J.W.1
-
28
-
-
79551588807
-
Beyond chemotherapy: New agents for targeted treatment of lymphoma
-
Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011;8:85-96.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, pp. 85-96
-
-
Younes, A.1
-
29
-
-
0035281784
-
2-(Fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial
-
Buchmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889-899.
-
(2001)
Cancer
, vol.91
, pp. 889-899
-
-
Buchmann, I.1
Reinhardt, M.2
Elsner, K.3
-
30
-
-
79955833418
-
Role of functional imaging in the management of lymphoma
-
Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844-1854.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1844-1854
-
-
Cheson, B.D.1
-
31
-
-
0036124658
-
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
-
Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112:262-268.
-
(2002)
Am J Med
, vol.112
, pp. 262-268
-
-
Wirth, A.1
Seymour, J.F.2
Hicks, R.J.3
-
32
-
-
0035863387
-
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: Is [18F]FDG-PETa valid alternative to conventional diagnostic methods?
-
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: is [18F]FDG-PETa valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19:414-419.
-
(2001)
J Clin Oncol
, vol.19
, pp. 414-419
-
-
Spaepen, K.1
Stroobants, S.2
Dupont, P.3
-
33
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
-
(2007)
J Clin Oncol
, vol.25
, pp. 579-586
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
-
34
-
-
33947512956
-
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
-
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
-
(2007)
J Clin Oncol
, vol.25
, pp. 571-578
-
-
Juweid, M.E.1
Stroobants, S.2
Hoekstra, O.S.3
-
35
-
-
64649093421
-
Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review
-
Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1906-1914
-
-
Terasawa, T.1
Lau, J.2
Bardet, S.3
-
36
-
-
84856799681
-
Treatment of limited stage DLBCL can be effectively tailored using a PET-based approach
-
abstract 028
-
Sehn LH, SavageKJ, Hoskins P, et al. Treatment of limited stage DLBCL can be effectively tailored using a PET-based approach. Ann Oncol. 2011;22:abstract 028.
-
(2011)
Ann Oncol
, vol.22
-
-
Sehn, L.H.1
Savagekj Hoskins, P.2
-
37
-
-
79960685420
-
How i treat primary CNS lymphoma
-
Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118:510-522.
-
(2011)
Blood
, vol.118
, pp. 510-522
-
-
Ferreri, A.J.1
-
38
-
-
79960239204
-
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial
-
Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766-2772.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2766-2772
-
-
Vitolo, U.1
Chiappella, A.2
Ferreri, A.J.3
-
39
-
-
77956331404
-
Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
-
Hui D, Proctor B, Donaldson J, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma. 2010;51:1658-1667.
-
(2011)
Leuk Lymphoma
, vol.51
, pp. 1658-1667
-
-
Hui, D.1
Proctor, B.2
Donaldson, J.3
-
40
-
-
21044457512
-
Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin
-
Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005; 23:2797-2804.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2797-2804
-
-
Lopez-Guillermo, A.1
Colomo, L.2
Jimenez, M.3
-
41
-
-
1642499119
-
Diffuse large B-cell lymphoma: Clinical implications of extranodal versus nodal presentationVa population-based study of 1575 cases
-
Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentationVa population-based study of 1575 cases. Br J Haematol. 2004;124:151-159.
-
(2004)
Br J Haematol
, vol.124
, pp. 151-159
-
-
Moller, M.B.1
Pedersen, N.T.2
Christensen, B.E.3
-
42
-
-
77954103840
-
Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era
-
Gutierrez-Garcia G, Colomo L, Villamor N, et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010;51:1225-1232.
-
(2011)
Leuk Lymphoma
, vol.51
, pp. 1225-1232
-
-
Gutierrez-Garcia, G.1
Colomo, L.2
Villamor, N.3
-
43
-
-
4143066762
-
Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restagingVdo we need contrast-enhanced CT?
-
Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restagingVdo we need contrast-enhanced CT? Radiology. 2004; 232:823-829.
-
(2004)
Radiology
, vol.232
, pp. 823-829
-
-
Schaefer, N.G.1
Hany, T.F.2
Taverna, C.3
-
44
-
-
84857920618
-
Late effects in the era of modern therapy for Hodgkin lymphoma
-
Burns LJ, Mikhaell JR, Schwartz BS et al, eds Washington, DC: American Society of Hematology
-
Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. In: Burns LJ, Mikhaell JR, Schwartz BS et al, eds. Hematology. Washington, DC: American Society of Hematology; 2011:323-329.
-
(2011)
Hematology
, pp. 323-329
-
-
Hodgson, D.C.1
-
45
-
-
23144457283
-
Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma
-
Brennan P, Scelo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer. 2005;93:159-166.
-
(2005)
Br J Cancer
, vol.93
, pp. 159-166
-
-
Brennan, P.1
Scelo, G.2
Hemminki, K.3
-
46
-
-
42949157852
-
Risk of subsequent solid tumors after non-Hodgkin's lymphoma: Effect of diagnostic age and time since diagnosis
-
Hemminki K, Lenner P, Sundquist J, et al. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol. 2008;26:1850-1857.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1850-1857
-
-
Hemminki, K.1
Lenner, P.2
Sundquist, J.3
-
47
-
-
33645745882
-
Risk of second malignancy after non-Hodgkin's lymphoma: A British Cohort study
-
Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort study. J Clin Oncol. 2006;24:1568-1574.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1568-1574
-
-
Mudie, N.Y.1
Swerdlow, A.J.2
Higgins, C.D.3
-
48
-
-
33745311546
-
The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma
-
Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108-115.
-
(2006)
Cancer
, vol.107
, pp. 108-115
-
-
Tward, J.D.1
Wendland, M.M.2
Shrieve, D.C.3
-
49
-
-
84865347010
-
Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: Involved-field versus involved-node radiotherapy
-
Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer. 2012;118:4156-4165.
-
(2012)
Cancer
, vol.118
, pp. 4156-4165
-
-
Campbell, B.A.1
Connors, J.M.2
Gascoyne, R.D.3
|